
1. antimicrob agents chemother. 2015 oct 12;60(1):613-6. doi: 10.1128/aac.01668-15. 
print 2016 jan.

the clinically tested gardos channel inhibitor senicapoc exhibits antimalarial
activity.

tubman vn(1), mejia p(2), shmukler be(3), bei ak(4), alper sl(5), mitchell jr(2),
brugnara c(6), duraisingh mt(7).

author information: 
(1)department immunology infectious diseases, harvard school public
health, boston, massachusetts, usa division hematology/oncology, boston
children's hospital, boston, massachusetts, usa department pediatrics, harvard
medical school, boston, massachusetts, usa.
(2)department genetics complex diseases, harvard school public health, 
boston, massachusetts, usa.
(3)renal division vascular biology research center, beth israel deaconess
medical center, boston, massachusetts, usa.
(4)department immunology infectious diseases, harvard school public
health, boston, massachusetts, usa.
(5)renal division vascular biology research center, beth israel deaconess
medical center, boston, massachusetts, usa department medicine, harvard
medical school, boston, massachusetts, usa.
(6)department laboratory medicine, boston children's hospital, boston,
massachusetts, usa carlo.brugnara@childrens.harvard.edu
mduraisi@hsph.harvard.edu.
(7)department immunology infectious diseases, harvard school public
health, boston, massachusetts, usa carlo.brugnara@childrens.harvard.edu
mduraisi@hsph.harvard.edu.

senicapoc, gardos channel inhibitor, prevented erythrocyte dehydration in
clinical trials patients sickle cell disease. tested hypothesis
that senicapoc-induced blockade gardos channel inhibits plasmodium growth.
senicapoc inhibited vitro growth human primate plasmodia the
clinical blood stage. senicapoc treatment suppressed p. yoelii parasitemia in
vivo c57bl/6 mice. reassuring safety biochemical profile senicapoc 
encourage use antimalarial development.

copyright Â© 2015, american society microbiology. rights reserved.

doi: 10.1128/aac.01668-15 
pmcid: pmc4704178
pmid: 26459896  [indexed medline]

